Company news
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) news
Apellis Pharmaceuticals, Inc. news releases on 6ix. Latest, Jun 10, 2024: SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE…
Press releases — page 2
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
June 9, 2024
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
May 23, 2024
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
May 13, 2024
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 6, 2024
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
May 5, 2024
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 30, 2024
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
April 25, 2024
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
April 22, 2024
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
March 31, 2024
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
March 10, 2024
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
February 19, 2024
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
January 25, 2024
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
January 7, 2024
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 1, 2024
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
December 27, 2023
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
December 13, 2023
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
December 10, 2023
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
November 20, 2023
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
November 3, 2023
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
October 31, 2023
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
October 24, 2023
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
October 19, 2023
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
October 16, 2023
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
October 4, 2023
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
October 1, 2023
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
September 24, 2023
Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success
August 28, 2023
Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)
August 21, 2023
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
July 30, 2023
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
July 29, 2023
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
July 28, 2023
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
July 23, 2023
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 9, 2023
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 6, 2023
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
May 24, 2023
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
May 3, 2023
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
May 2, 2023
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
April 26, 2023
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
April 22, 2023
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
April 20, 2023
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
April 16, 2023
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
February 26, 2023
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
February 21, 2023
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
February 21, 2023
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
February 20, 2023
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
February 16, 2023
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
January 4, 2023
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023